ライフサイエンスコーパス: laryngeal cancer

1 -preservation strategies in the treatment of laryngeal cancer.

2 functional preservation in locally advanced laryngeal cancer.

3 ible with IMRT and IGRT for locally advanced laryngeal cancer.

4 tration or extralaryngeal spread of advanced laryngeal cancer.

5 modify smoking and drinking odds ratios for laryngeal cancer.

6 essity for initial laryngectomy for advanced laryngeal cancer.

7 yngectomy for patients with locally advanced laryngeal cancer.

8 o identify primary and recurrent early stage laryngeal cancer.

9 workup of patients with oral, pharyngeal, or laryngeal cancer.

10 studies (1981-2006) of oral, pharyngeal, and laryngeal cancers (6,772 cases and 8,375 controls) in th

11 ncurrent chemoradiation for locally advanced laryngeal cancers (8 IMRT, 19 IGRT) was undertaken.

12 For the patient with laryngeal cancer, a partial response was sustained for 1

13 benefit in local tumor control for advanced laryngeal cancers, a significant gain in regional contro

14 tomography/computed tomography (PET/CT) for laryngeal cancers after inadequate CT results.

15 nduction schedules to patients with advanced laryngeal cancer allows greater organ preservation witho

16 We describe a 49-year-old man with laryngeal cancer and right pleural space infection with

17 similar trend exists, albeit less marked, in laryngeal cancers and in head and neck cancers.

18 or upfront laryngectomy in the management of laryngeal cancer are a functionless larynx and extralary

19 Laryngeal cancers are characterized by high recurrence a

20 vasive, real-time diagnosis and detection of laryngeal cancer at the molecular level.

21 chemoradiotherapy in patients with advanced laryngeal cancer can achieve high rates of organ preserv

22 y alone in selected patients with T2-4, N0-1 laryngeal cancer can provide durable disease remission a

23 8 oro-/hypopharyngeal cancer (OHPs), and 193 laryngeal cancer cases] were available for analysis.

24 5; the Rhein-Neckar Larynx Study, a study of laryngeal cancer conducted in 1998-2000; and a lung canc

25 utcomes among patients having oral-cavity or laryngeal cancers even when standard disease staging was

26 reated docetaxel-resistant DRHEp2 from human laryngeal cancer HEp2 and investigated the roles of mito

27 (65/72) and specificity of 90.9% (20/22) for laryngeal cancer identification.

28 For patients investigated for laryngeal cancer in which CT is considered inadequate, d

29 Larynx preservation in advanced, resectable laryngeal cancer may be achieved using induction chemoth

30 ith histologically proven pancreatic cancer, laryngeal cancer, non-small cell lung cancer, prostate c

31 pattern was positively associated only with laryngeal cancer (odds ratio = 2.12, 95% confidence inte

32 mprised 45 patients investigated for primary laryngeal cancer or recurrence-residue in which CT was c

33 About two thirds of laryngeal cancers originate at the vocal cords.

34 , while smoking odds ratios were greater for laryngeal cancer (P < 0.01).

35 dependent validation cohort consisting of 63 laryngeal cancer patients.

36 For patients with stage II to IV laryngeal cancer, radiation therapy (RT) either alone or

37 In patients with laryngeal cancer, radiotherapy with concurrent administr

38 Patients with advanced laryngeal cancer received two cycles of cisplatin 100 mg

39 Significant excesses of laryngeal cancer (relative risk 7.67, based on two possi

40 ttes/day varied, indicating that the greater laryngeal cancer risk derived from differential cigarett

41 Recommendations Patients with T1, T2 laryngeal cancer should be treated initially with intent

42 ; 95% confidence interval (CI): 11.3, 27.4], laryngeal cancer (SMR = 8.1; 95% CI: 3.5, 16.0), liver c

43 methylation, we for the first time identify laryngeal cancer subtypes with distinct prognostic outco

44 objectives were to study the sensitivity of laryngeal cancer to platinum-based chemotherapy alone an

45 Twelve patients with T1 or T2 laryngeal cancer underwent imaging prospectively with PE

46 herapy alone may cure selected patients with laryngeal cancer, warranting further prospective investi

47 Only 6/22 (27%) of the laryngeal cancers we examined demonstrated LOH of the BR

48 Patients with cT2-4 squamous cell laryngeal cancer were randomly assigned to AR (68 Gy wit

49 All patients with T1 or T2 laryngeal cancer, with rare exception, should be treated

50 ore individuals affected by lung, throat, or laryngeal cancer, yielded a maximum heterogeneity LOD sc